Exact Mass: 443.3372462
Exact Mass Matches: 443.3372462
Found 219 metabolites which its exact mass value is equals to given mass value 443.3372462,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dynorphin A (6-8)
C18H37N9O4 (443.29683620000003)
Dynorphin A (6-8) is a fraction of Dynorphin A with only Arg-Arg-Ile peptide chain. Dynorphin A is an endogenous opioid peptide that produces non-opioid receptor-mediated neural excitation.Dynorphin induces calcium influx via voltage-sensitive calcium channels in sensory neurons by activating bradykinin receptors. This action of dynorphin at bradykinin receptors is distinct from the primary signaling pathway activated by bradykinin and underlies the hyperalgesia produced by pharmacological administration of dynorphin by the spinal route in rats and mice. Blockade of spinal B1 or B2 receptor also reverses persistent neuropathic pain but only when there is sustained elevation of endogenous spinal dynorphin, which is required for maintenance of neuropathic pain. These data reveal a mechanism for endogenous dynorphin to promote pain through its agonist action at bradykinin receptors and suggest new avenues for therapeutic intervention. Dynorphin A is a form of dynorphin.Dynorphins are a class of opioid peptides that arise from the precursor protein prodynorphin. When prodynorphin is cleaved during processing by proprotein convertase 2 (PC2), multiple active peptides are released: dynorphin A, dynorphin B, and a/b-neo-endorphin. Depolarization of a neuron containing prodynorphin stimulates PC2 processing, which occurs within synaptic vesicles in the presynaptic terminal. Occasionally, prodynorphin is not fully processed, leading to the release of "big dynorphin."This 32-amino acid molecule consists of both dynorphin A and dynorphin B.Dynorphin A, dynorphin B, and big dynorphin all contain a high proportion of basic amino acid residues, in particular lysine and arginine (29.4\\%, 23.1\\%, and 31.2\\% basic residues, respectively), as well as many hydrophobic residues (41.2\\%, 30.8\\%, and 34.4\\% hydrophobic residues, respectively). Although dynorphins are found widely distributed in the CNS, they have the highest concentrations in the hypothalamus, medulla, pons, midbrain, and spinal cord. Dynorphins are stored in large (80-120 nm diameter) dense-core vesicles that are considerably larger than vesicles storing neurotransmitters. These large dense-core vesicles differ from small synaptic vesicles in that a more intense and prolonged stimulus is needed to cause the large vesicles to release their contents into the synaptic cleft. Dense-core vesicle storage is characteristic of opioid peptides storage. The first clues to the functionality of dynorphins came from Goldstein et al. in their work with opioid peptides. The group discovered an endogenous opioid peptide in the porcine pituitary that proved difficult to isolate. By sequencing the first 13 amino acids of the peptide, they created a synthetic version of the peptide with a similar potency to the natural peptide. Goldstein et al. applied the synthetic peptide to the guinea ileum longitudinal muscle and found it to be an extraordinarily potent opioid peptide. The peptide was called dynorphin (from the Greek dynamis=power) to describe its potency. Dynorphins exert their effects primarily through the κ-opioid receptor (KOR), a G-protein-coupled receptor. Two subtypes of KORs have been identified: K1 and K2. Although KOR is the primary receptor for all dynorphins, the peptides do have some affinity for the μ-opioid receptor (MOR), d-opioid receptor (DOR), N-methyl-D-aspartic acid (NMDA)-type glutamate receptor. Different dynorphins show different receptor selectivities and potencies at receptors. Big dynorphin and dynorphin A have the same selectivity for human KOR, but dynorphin A is more selective for KOR over MOR and DOR than is big dynorphin. Big dynorphin is more potent at KORs than is dynorphin A. Both big dynorphin and dynorphin A are more potent and more selective than dynorphin B (Wikipedia). Dynorphin A (6-8) is a fraction of Dynorphin A with only Arg-Arg-Ile peptide chain
12-Hydroxy-12-octadecanoylcarnitine
C25H49NO5 (443.36105440000006)
12-Hydroxy-12-octadecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-Hydroxy-12-octadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-hydroxy-12-octadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 12-hydroxy-12-octadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
3-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
3-Hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 3-Hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
10-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
10-Hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-Hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-Hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 10-Hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
9-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
9-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 9-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
13-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
13-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 13-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
5-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 5-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
7-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 7-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
8-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
8-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 8-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
11-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
11-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 11-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
6-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular 6-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with coronary artery disease (PMID: 20173117). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2S)-2-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
(2S)-2-hydroxyoctadecanoylcarnitine is an acylcarnitine. More specifically, it is an (2S)-2-hydroxyoctadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2S)-2-hydroxyoctadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (2S)-2-hydroxyoctadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. In particular (2S)-2-hydroxyoctadecanoylcarnitine is elevated in the blood or plasma of individuals with carnitine-acylcarnitine translocase deficiency (PMID: 12403251), chronic fatigue syndrome (PMID: 21205027), pulmonary Arterial Hypertension (PMID: 27006481), carnitine palmitoyl Transferase 2 Deficiency (PMID: 15653102), cardiovascular mortality in chronic kidney disease (PMID: 24308938), diastolic heart failure (PMID: 27473038), and systolic heart failure (PMID: 27473038). It is also decreased in the blood or plasma of individuals with intracerebral hemorrhage (PMID: 29265114), and carnitine palmitoyl transferase 1A deficiency (PMID: 11568084). Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Linoleoyl Tyrosine
C27H41NO4 (443.30354260000007)
N-linoleoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate can be found in a number of food items such as cornmint, black elderberry, garden rhubarb, and black radish, which makes 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate a potential biomarker for the consumption of these food products.
(23R)-17,23-epoxy-3beta,14-dihydroxy-(5alpha)-veratr-13(18)-en-6-one|Edpetin|edpetine
C27H41NO4 (443.30354260000007)
2-(14-Hydroxy-14,15-dimethylhexadecyl)-3-methoxyquinoline-4(1H)-one
Yibeissine
C27H41NO4 (443.30354260000007)
Yibeissine is a steroidal alkaloid isolated from the bulb of Fritillaria pallioiflora Schren[1]. Yibeissine is a steroidal alkaloid isolated from the bulb of Fritillaria pallioiflora Schren[1].
C27H41NO4_(7E)-3-Isobutyl-4,5,8,12,12-pentamethyl-3,3a,4,6a,9,10,10a,13a,14,15-decahydro-1H-[1,3]dioxolo[7,8]cycloundeca[1,2-d]isoindole-1,16(2H)-dione
C27H41NO4 (443.30354260000007)
Ala Ile Ile Lys
C21H41N5O5 (443.31075360000006)
Ala Ile Lys Ile
C21H41N5O5 (443.31075360000006)
Ala Ile Lys Leu
C21H41N5O5 (443.31075360000006)
Ala Ile Leu Lys
C21H41N5O5 (443.31075360000006)
Ala Lys Ile Ile
C21H41N5O5 (443.31075360000006)
Ala Lys Ile Leu
C21H41N5O5 (443.31075360000006)
Ala Lys Leu Ile
C21H41N5O5 (443.31075360000006)
Ala Lys Leu Leu
C21H41N5O5 (443.31075360000006)
Ala Leu Ile Lys
C21H41N5O5 (443.31075360000006)
Ala Leu Lys Ile
C21H41N5O5 (443.31075360000006)
Ala Leu Lys Leu
C21H41N5O5 (443.31075360000006)
Ala Leu Leu Lys
C21H41N5O5 (443.31075360000006)
Ile Ala Ile Lys
C21H41N5O5 (443.31075360000006)
Ile Ala Lys Ile
C21H41N5O5 (443.31075360000006)
Ile Ala Lys Leu
C21H41N5O5 (443.31075360000006)
Ile Ala Leu Lys
C21H41N5O5 (443.31075360000006)
Ile Ile Ala Lys
C21H41N5O5 (443.31075360000006)
Ile Ile Lys Ala
C21H41N5O5 (443.31075360000006)
Ile Lys Ala Ile
C21H41N5O5 (443.31075360000006)
Ile Lys Ala Leu
C21H41N5O5 (443.31075360000006)
Ile Lys Ile Ala
C21H41N5O5 (443.31075360000006)
Ile Lys Leu Ala
C21H41N5O5 (443.31075360000006)
Ile Leu Ala Lys
C21H41N5O5 (443.31075360000006)
Ile Leu Lys Ala
C21H41N5O5 (443.31075360000006)
Lys Ala Ile Ile
C21H41N5O5 (443.31075360000006)
Lys Ala Ile Leu
C21H41N5O5 (443.31075360000006)
Lys Ala Leu Ile
C21H41N5O5 (443.31075360000006)
Lys Ala Leu Leu
C21H41N5O5 (443.31075360000006)
Lys Ile Ala Ile
C21H41N5O5 (443.31075360000006)
Lys Ile Ala Leu
C21H41N5O5 (443.31075360000006)
Lys Ile Ile Ala
C21H41N5O5 (443.31075360000006)
Lys Ile Leu Ala
C21H41N5O5 (443.31075360000006)
Lys Leu Ala Ile
C21H41N5O5 (443.31075360000006)
Lys Leu Ala Leu
C21H41N5O5 (443.31075360000006)
Lys Leu Ile Ala
C21H41N5O5 (443.31075360000006)
Lys Leu Leu Ala
C21H41N5O5 (443.31075360000006)
Lys Val Val Val
C21H41N5O5 (443.31075360000006)
Leu Ala Ile Lys
C21H41N5O5 (443.31075360000006)
Leu Ala Lys Ile
C21H41N5O5 (443.31075360000006)
Leu Ala Lys Leu
C21H41N5O5 (443.31075360000006)
Leu Ala Leu Lys
C21H41N5O5 (443.31075360000006)
Leu Ile Ala Lys
C21H41N5O5 (443.31075360000006)
Leu Ile Lys Ala
C21H41N5O5 (443.31075360000006)
Leu Lys Ala Ile
C21H41N5O5 (443.31075360000006)
Leu Lys Ala Leu
C21H41N5O5 (443.31075360000006)
Leu Lys Ile Ala
C21H41N5O5 (443.31075360000006)
Leu Lys Leu Ala
C21H41N5O5 (443.31075360000006)
Leu Leu Ala Lys
C21H41N5O5 (443.31075360000006)
Leu Leu Lys Ala
C21H41N5O5 (443.31075360000006)
Val Lys Val Val
C21H41N5O5 (443.31075360000006)
Val Val Lys Val
C21H41N5O5 (443.31075360000006)
Val Val Val Lys
C21H41N5O5 (443.31075360000006)
diethyl amide
C27H41NO4 (443.30354260000007)
CAR 18:0;O
C25H49NO5 (443.36105440000006)
tris(2-hydroxyethyl)ammonium tetradecyl sulphate
C20H45NO7S (443.29165800000004)
ammonium hydroxydinonylbenzenesulphonate
C24H45NO4S (443.30691300000007)
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate can be found in a number of food items such as cornmint, black elderberry, garden rhubarb, and black radish, which makes 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate a potential biomarker for the consumption of these food products. 3β-hydroxy-4β-methyl-5α-cholest-7-ene-4α-carboxylate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 3β-hydroxy-4β-methyl-5α-cholest-7-ene-4α-carboxylate can be found in a number of food items such as cornmint, black elderberry, garden rhubarb, and black radish, which makes 3β-hydroxy-4β-methyl-5α-cholest-7-ene-4α-carboxylate a potential biomarker for the consumption of these food products.
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate
3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate can be found in a number of food items such as cornmint, black elderberry, garden rhubarb, and black radish, which makes 3beta-hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate a potential biomarker for the consumption of these food products.
3beta-Hydroxy-4beta-methyl-5alpha-cholest-8-ene-4alpha-carboxylate
A steroid acid anion that is the conjugate base of 3beta-hydroxy-4beta-methyl-5alpha-cholest-8-ene-4alpha-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
3beta-Hydroxy-4beta-methyl-5alpha-cholest-7-ene-4alpha-carboxylate
4beta-Carboxy-4alpha-methyl-5alpha-cholesta-8-en-3beta-ol
3beta-Hydroxy-4alpha-methyl-5alpha-cholest-7-ene-4beta-carboxylate
3-(4-hydroxyphenyl)-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]propanoic acid
C27H41NO4 (443.30354260000007)
(2S)-2-Hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
(12E)-7,7,12,16,17-pentamethyl-19-(2-methylpropyl)-6,8-dioxa-20-azatetracyclo[12.7.0.01,18.05,9]henicosa-12,15-diene-2,21-dione
C27H41NO4 (443.30354260000007)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(4-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(2-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-9-[[methyl-[(3-methylphenyl)methyl]amino]methyl]-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-5-one
C24H37N5O3 (443.28962520000005)
19-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]nonadecanoate
(17R)-17-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxooctadecanoate
18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxooctadecanoate
(18R)-18-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxynonadecanoate
(5Z,8Z,11Z,14Z,17Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]icosa-5,8,11,14,17-pentaenamide
(4Z,7Z,10Z,13Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexadeca-4,7,10,13-tetraenamide
(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide
12-Hydroxy-12-octadecanoylcarnitine
C25H49NO5 (443.36105440000006)
3-hydroxyoctadecanoylcarnitine
C25H49NO5 (443.36105440000006)
An O-acylcarnitine having 3-hydroxyoctadecanoyl as the acyl substituent.
oscr#34(1-)
A monocarboxylic acid anion that is the conjugate base of oscr#34, obtained by deprotonation of the carboxy group; major species at pH 7.3.
CarE(18:0)
C25H49NO5 (443.36105440000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1r,2s,4s,7s,8r,9s,12s,13s)-16-amino-7-(3,4-dimethylpent-4-en-1-yl)-7-hydroxy-9,13-dimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one
2-methyl-6-(11-oxododecyl)piperidin-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
C27H41NO4 (443.30354260000007)
2-(14-hydroxy-14,15-dimethylhexadecyl)-3-methoxy-1h-quinolin-4-one
24-hydroxyimino-29-norcycloart-3-ol
{"Ingredient_id": "HBIN004410","Ingredient_name": "24-hydroxyimino-29-norcycloart-3-ol","Alias": "NA","Ingredient_formula": "C29H49NO2","Ingredient_Smile": "CC1C2CCC3C4(CCC(C4(CCC35C2(C5)CCC1O)C)C(C)CCC(=NO)C(C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15860","TCMID_id": "10229","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1r,2s,4s,7s,8r,9s,12s,13s,16s,18s)-16-amino-7-[(1e,3r)-3,4-dimethylpent-1-en-1-yl]-7-hydroxy-9,13-dimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one
2,3-dimethoxy-6-(10-methoxy-3,7,9,11-tetramethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
(3s,4as,6ar,6bs,9r,11as,11br)-3-hydroxy-9-[(1r)-1-[(2r,3r,5r)-3-hydroxy-1,5-dimethylpiperidin-2-yl]ethyl]-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one
2-[(14r)-14-hydroxy-14,15-dimethylhexadecyl]-3-methoxy-1h-quinolin-4-one
(3s,4as,6ar,6bs,9s,11as,11br)-3-hydroxy-9-[(1r)-1-[(2r,3r,5r)-3-hydroxy-1,5-dimethylpiperidin-2-yl]ethyl]-10,11b-dimethyl-1h,2h,3h,4h,4ah,6h,6ah,6bh,7h,8h,9h,11h,11ah-cyclohexa[a]fluoren-5-one
2,3-dimethoxy-6-(10-methoxy-3,5,7,9,11-pentamethyltrideca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
(4s,7s,8r,9s,13s,16s)-16-amino-7-[(1e)-3,4-dimethylpent-1-en-1-yl]-7-hydroxy-9,13-dimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one
2,3-dimethoxy-6-[(2e,5e,7e,9r,10r,11e)-10-methoxy-3,7,9,11-tetramethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
(1's,2s,3s,3'r,5r,7'r,13's,15'r)-15'-hydroxy-12'-(2-hydroxyethyl)-3,3',15'-trimethyl-5-(2-methylprop-1-en-1-yl)-12'-azaspiro[oxolane-2,6'-tetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadecan]-10'(16')-en-11'-one
C27H41NO4 (443.30354260000007)
16-amino-7-(3,4-dimethylpent-1-en-1-yl)-7-hydroxy-9,13-dimethyl-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6-one
3,11-dihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-5-one
C27H41NO4 (443.30354260000007)
(3s,3'r,3'as,4as,6's,6as,6bs,7'ar,9r,11r,11as,11br)-3,11-dihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5',6,6',6a,6b,7,7',7'a,8,11,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-5-one
C27H41NO4 (443.30354260000007)
2-methyl-6-(11-oxododecyl)piperidin-3-yl 3-(4-hydroxyphenyl)prop-2-enoate
C27H41NO4 (443.30354260000007)
1,3-dihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H41NO4 (443.30354260000007)
2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,7,9,11-tetramethyltetradeca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
(1s,3r,3'r,3'as,4as,6's,6as,6bs,7'ar,9r,11as,11bs)-1,3-dihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H41NO4 (443.30354260000007)
2,3-dimethoxy-6-[(2e,5e,7e,9s,10s,11e)-10-methoxy-3,5,7,9,11-pentamethyltrideca-2,5,7,11-tetraen-1-yl]-5-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
2-[(2e,5e,7e,11z)-10-hydroxy-3,7,9,11,13-pentamethyltetradeca-2,5,7,11-tetraen-1-yl]-5,6-dimethoxy-3-methylpyridin-4-ol
C27H41NO4 (443.30354260000007)
(1r,3r,3'r,3'as,4ar,6's,6as,6bs,7'ar,9r,11as,11bs)-1,3-dihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
C27H41NO4 (443.30354260000007)